Abstract：Objective To investigate the curative effect of sitagliptin combined with metformin in the treatment of hyperglycemia metabolic syndrome.Methods A total of 75 patients with hyperglycemia metabolic syndrome admitted in our hospital from Jan 2013 to Jun 2014 were selected and divided randomly into the observation group (n=37) and control group (n=38). Same diet and exercise plan were given to the two groups. Then the observation group was given sitagliptin and metformin treatment, while the control group was given metformin treatment for 12 weeks. The waist circumference (WC), body mass index (BMI), blood glucose, blood lipid, fasting insulin, serum adiponectin and other biochemical indicators were detected and compared. The steady-state model of insulin resistance index (HOMA-IR) and whole body insulin sensitivity index (WBISI) were calculated.Results After treatment, there were statistically differences (P<0.05) between the two groups in WC, BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP), triglycerides (TG), cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), fasting plasma glucose (FPG), 2 h postprandial blood glucose (2 h PG), fasting insulin (FINS), HOMA-IR, WBISI and serum adiponectin; The above indexes of the observation group and control group were both obviously improved, and the improved effect of observation group was significantly better than that of the control group (P<0.05).Conclusion The sitagliptin combined with metformin has better curative effect in treatment of hyperglycemia metabolic syndrome.
〔1〕 姚崇华,胡以松,翟风英,等.我国2002年代谢综合征的流行情况〔J〕.中国糖尿病杂志,2007,15(6):332. 〔2〕 SAKAMOTO Y,OYAMA JI,IKEDA H,et al.Effects of sitagliptin beyond glycemic control: focus on quality of life〔J〕.Cardiovascular Diabetology,2013,12(8):900. 〔3〕 中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议〔J〕.中国糖尿病杂志,2004(3):156. 〔4〕 王传海,王新江,田慧,等.老年人腹部脂肪(CT测量)分布与体质指数及代谢综合征的关系〔J〕.中华医学杂志,2014,94(12):908. 〔5〕 SUN S,WU H,ZHANG Q,et al.Subnormal peripheral blood leukocyte counts are related to the lowest prevalence and incidence of metabolic syndrome:tianjin chronic low- grade systemic inflammation and health cohort study〔J〕.Mediators of Inflammation,2014,4(6):386. 〔6〕 严婷,李玲玲,王怀明,等.2型糖尿病患者脂肪细胞因子与代谢综合征的关系〔J〕.南方医科大学学报,2014,34(2):275. 〔7〕 BOYRAZ M,CEKMEZ F,KARAO GLU A,et al.Relationship of adipokines (adiponectin, resistin and RBP4) with metabolic syndrome components in pubertal obese children〔J〕. Biomarkers in Medicine,2013,7(3):423. 〔8〕 KIM J W,KANG K M,YOON T K,et al.Study of circulating hepcidin in association with iron excess, metabolic syndrome, and BMP-6 expression in granulosa cells in women with polycystic ovary syndrome〔J〕.Fertil Steril,2014,6(5): 26. 〔9〕 彭永,吕肖锋.维生素D与2型糖尿病的相关性研究进展〔J〕.解放军医药杂志, 2015(4):112. 〔10〕 罗艳侠,郭秀花,王玮,等.代谢综合征血糖异常组分影响因素研究〔J〕.中国预防医学杂志,2010(2):147. 〔11〕 徐晓峰,吴升,吴敏魁.营养干预对代谢综合征患者脂代谢影响的研究〔J〕.临床军医杂志,2011,39(1):17. 〔12〕 李萍.从对IR的影响评价降压降糖降脂类药物的选择〔J〕.武警后勤学院学报:医学版,2014(8):710. 〔13〕 曹凯,王友信,刘相佟,等.血浆糖基与代谢综合征血糖组分关联性研究〔J〕.首都医科大学学报,2015(4):614. 〔14〕 张允.影响糖耐量正常人群口服糖耐量1小时血糖水平的相关因素分析〔D〕.安徽医科大学,2015. 〔15〕 信中,马亚红,赵蕾,等代谢综合征与口服糖耐量试验1小时血糖的相关性研究〔J〕.中国全科医学,2012,15(3):249. 〔16〕 王峥,王菲菲,朱晓健,等.社区高血糖人群伴随代谢综合征及微量白蛋白尿的分析〔J〕.中华医学杂志,2012,92(36):252. 〔17〕 张磊,马凤海,李娟娟,等.血糖正常人群不同空腹及口服葡萄糖耐量试验2 h血糖水平与代谢综合征的关系〔J〕.中国糖尿病杂志,2012,4(4):247. 〔18〕 赵岩,程坤鹏,张强,等.血糖变异在代谢综合征患者和正常人群中的临床比较研究〔J〕.中国实验诊断学,2015(9):1553. 〔19〕 仇梦霞,龙石银,陈志军,等.代谢综合征患者血糖、血脂水平与HDL亚类组成的关系〔J〕.中国病理生理杂志,2015(2):319. 〔20〕 周爱民,戴霞,陈财英,等.自我效能理论在代谢综合征患者血糖控制中的应用〔J〕.中国临床新医学,2014(2):164. 〔21〕 SAKAMOTO Y, OYAMA J I, IKEDA H,et al. Effects of sitagliptin beyond glycemic control: focus on quality of life〔J〕.Cardiovascular Diabetology, 2013,12(8):900. 〔22〕 MONAMI M, LAMANNA C, DESIDERI C M,et al.DPP-4 inhibitors and lipids:systematic review and Meta-analysis〔J〕.Adv Ther,2012,29(1):14. 〔23〕 KOJIMA Y,KAGA H, HAYASHI S,et al.Comparison between sitagliptin and nateglinide on postprandial lipid levels:the STANDARD study〔J〕.World Diabetes,2013,4(1):8. 〔24〕 WHITE WB, PRATLEY R, FLECK P,et al.Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus〔J〕.Diabetes Obes Metab,2013,15(7):668. 〔25〕 GREEN J B,BETHEL M A,PAUL S K ,et al. Rationale,design,and organization of a randomized, controlled Trial Evaluating Crardiovascular Outcomes with Sitagliptin(TECOS) in patients with type 2 diabetes and established cardiovascular disease〔J〕.Am Heart J,2013,166(6):983. 〔26〕 DEROSA G,RAGONESI P D,FOGARI E,et al. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile:a 2-year study evaluation〔J〕.Fundam Clin Pharmacol,2014,28(2):221.
No related articles found!
Viewed
Full text
Abstract
Cited
Shared
Discussed
[an error occurred while processing this directive]
2016, Vol. 34 
